What caused the pre-market spike in 2289.HK stock?

The pre-market spike to **HK$7.31** likely reflects short-term buying interest and volume at **1,000** shares. No major public release is logged; watch official company updates and trade volume for confirmation of a sustained move in 2289.HK stock.

How cheap or expensive is 2289.HK stock versus peers?

2289.HK stock trades at **PE 14.62**, below the Healthcare sector average **PE 30.63**, and at **PB 1.19**, indicating relative value. Elevated debt-to-equity **1.78** offsets some valuation appeal.

What are realistic price targets for 2289.HK stock?

A conservative 12-month base price target is **HK$7.50**, a bull target **HK$9.50**, and a bear scenario **HK$5.00**. Targets reflect current volatility, year high **HK$9.74**, and year low **HK$5.13**.

Does Meyka AI provide a buy or sell recommendation for 2289.HK stock?

Meyka AI rates the stock **69.91 (Grade B)** with a **HOLD** suggestion. This considers sector comparison, growth, metrics, and forecasts. This is not personalised advice; conduct your own research before acting on 2289.HK stock.

HK Stocks

Pre-market: 2289.HK up 23.90% at HK$7.31 (17 Jan 2026): Check volume signal

ByDanny Kontos January 17, 2026

We see a strong pre-market move in the 2289.HK stock as Charmacy Pharmaceutical (HKSE) rallies 23.90% to HK$7.31 on 17 Jan 2026. The price gap follows a sharp rise from the previous close of HK$5.90, with trade volume at 1,000 shares versus an average of 441. This high-volume mover setup merits a quick read of valuation, technicals, and risks before traders position into the Hong Kong healthcare name.